8-K - LIXT - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 30, 2022

LIXTE

BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

delaware	001-39717	20-2903526
(State<br> or other jurisdiction of incorporation)	(Commission<br><br> <br>File<br> Number)	(I.R.S.<br> Employer<br><br> <br><br><br> <br>Identification<br> Number)

680 East Colorado Boulevard, Suite 180

Pasadena California

91101

(Address of principal executive offices)

(631) 830-7092

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

☐	Written<br> communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
☐	Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement<br> communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of Each Class	Trading<br> Symbol(s)	Name<br> of each exchange on which registered
Common<br> Stock, par value $0.0001 per share	LIXT	The<br> Nasdaq<br> Stock Market LLC
Warrants<br> to purchase Common Stock, par value $0.0001 per share	LIXTW	The<br> Nasdaq<br> Stock Market LLC

Item 7.01. Regulation FD Disclosure.

On November 30, 2022, the Company issued a press release to announce that it will be presenting at the Planet MicroCap Showcase: Virtual 2022 Investor Conference to be held on December 7, 2022 at 3:30 PM EST.

Attached as Exhibit 99.1 is the investor presentation which will be used at the conference. The presentation in whole or in part may also be used at subsequent meetings with investors, analysts, or others, and also will be subject to modification.

The information contained in this Current Report and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified therein as being incorporated by reference.

Item9.01 Financial Statements and Exhibits

(d) There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which exhibit is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:<br> December 6, 2022		LIXTE<br> BIOTECHNOLOGY HOLDINGS, INC.
	By:	/s/ JOHN S. KOVACH
		John<br> S. Kovach, Chief Executive Officer

INDEX

TO EXHIBITS

Exhibit No.	Description
99.1	Investor Presentation
104	Cover<br> Page Interactive Data File (embedded within the Inline XPRL Document)

Exhibit 99.1